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Abstract: The purpose of this study was to examine gender differences in mortality for human 
immunodeficiency virus (HIV) patients in rural Western Uganda after six months of highly active 
antiretroviral therapy (HAART). Three hundred eighty five patients were followed up for six 
months after initiating HAART. Statistical analysis included descriptive, univariate and multivari-
ate methods, using Kaplan–Meier estimates of survival distribution and Cox proportional hazards 
regression. Mortality in female patients (9.0%) was lower than mortality in males (13.5%), with 
the difference being almost statistically significant (adjusted hazard ratio for females 0.55; 95% 
confidence interval [CI]: 0.28–1.07; P = 0.08). At baseline, female patients had a significantly 
higher CD4+ cell count than male patients (median 147 cells/µL vs 120 cells/µL; P  0.01). 
A higher CD4+ cell count and primary level education were strongly associated with better 
survival. The higher CD4+ cell count in females may indicate that they accessed HAART 
services at an earlier stage of their disease progression than males. A borderline statistically 
significant lower mortality rate in females shows that females fare better on treatment in this 
context than males. The association between lower mortality and higher CD4+ levels suggest 
that males are not accessing treatment early enough and that more concerted efforts need to be 
made by HAART programs to reach male HIV patients.
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Introduction
Globally, gender differences in life expectancy have been well documented with life 
expectancies being generally higher for females than for males.1 The life expectancy gap 
is typically much narrower in developing countries compared to developed countries. 
For example life expectancy in less developed countries (following conventions used by 
the United Nations) is on average 61 years for males and 64 years for females, compared 
to 73 years for males and 80 years for females in more developed countries.2
Gender issues in human immunodeficiency virus (HIV) prevention and care 
have been on the research agenda for some time. Of concern is the growing gender 
imbalance of HIV-infection – where now more women than men are HIV-positive in 
sub-Saharan Africa – that has been documented in many African countries.3–5 When 
it comes to highly active antiretroviral therapy (HAART), Nicastri and colleagues, 
who completed several reviews of sex/gender-based differences in HAART outcomes, 
mostly in developed countries, concluded that it is important to conduct gender-sensitive 
HAART outcome studies in order to determine the sources of male–female outcome 
differences; specifically whether these differences are the result of biological sex dif-
ferences or socially-defined gender differences.6,7International Journal of Women’s Health 2010:2 46
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While studies have been undertaken in developing 
countries to look at differences in mortality between males 
and females, these studies have not focused on patients 
accessing treatment in rural and remote areas. Overall, these 
studies have found that females on HAART have a lower risk 
of mortality than males. These include studies in Malawi,8,9 
Cameroon,10 Nigeria,11 Botswana,12 and South Africa.13 In 
contrast to studies in Africa, studies from Brazil showed 
the opposite result where there was a significant increased 
risk of mortality for female HAART patients compared to 
male patients.14,15 Finally, a survey of HAART programs 
in low-income (Africa, Asia, and South America) and 
high-income (North America and Europe) countries found 
that overall in both settings there was an increased risk of 
mortality for males.16
Other gender differences in HIV treatment programs 
have also been reported. For example, gender differences 
in ART treatment outcomes have been reported in one 
study undertaken in Uganda and Zimbabwe, where females 
were found to have better ART outcomes then men.17 In 
developed countries, the findings are mixed. Better treatment 
outcomes for females have been reported in the United States 
of America (US),6 Switzerland,18 and the United Kingdom 
(UK),19 while no differences in outcomes have been observed 
in other studies from Italy7 and the UK.20 In addition, adverse 
reactions to HAART are reported more frequently and 
consistently in women compared to men from US, Canada, 
and Botswana.21–24 Gender differences in health-seeking 
behavior for HAART services have also been described in 
various countries such as Brazil14 and from several southern 
African countries where women who received HAART were 
younger and had a slower progression to clinical AIDS than 
men.25 Women were reported to be less adherent to HAART 
than men in Canada, US, and Italy.7,26,27 Health provider-
related gender differences were found in two areas of North 
America where women were less likely to receive a protease 
inhibitor containing HAART regimen or newly developed 
antiretroviral (ARV) drugs.28,29 Women on HAART in one 
part of the US were less likely to be referred to a hospital than 
men when HIV-related complications would have justified 
hospital treatment.30
To date, most research on mortality and treatment 
outcomes in sub-Saharan Africa have focused on urban 
areas. In order to investigate treatment outcomes in rural 
areas in sub-Saharan Africa, our research team evaluated 
the experiences of patients undergoing treatment between 
2006 and 2007 in the Kabarole District in Western Uganda. 
An estimated 22,400 individuals with HIV-infection reside 
in this predominantly rural district.31 HIV prevalence in 
the district is 11.6%,31 which is above the national average 
of 6.4%.32 In 2006, our team, in conjunction with the 
Kabarole Health District, implemented a community-
based antiretroviral therapy (CBART) program in Rwimi 
sub-county located within the Kabarole district. The primary 
objective of the intervention was to improve access to 
HAART for persons living with HIV/AIDS living in rural 
and remote areas. Results from the CBART study were 
compared with results from a nearby hospital-based HAART 
program. Though we did not have a specific gender emphasis 
in the establishment of the CBART program and in how we 
recruited the cohorts, we expected that bringing treatment 
closer to where rural populations live would increase access 
to treatment for women.
The purpose of our study was to examine whether gender 
differences existed in the outcomes of HAART, specifically 
all-cause mortality after six months of treatment for HIV 
patients in rural Western Uganda, and to identify factors 
associated with mortality in this population.
Methods
Study population
This was a prospective cohort study where patients enrolled 
on HAART were followed-up by our team for six months 
after starting on HAART. Our study sample consisted of 
treatment-naïve HIV patients who sequentially presented 
at either the CBART or hospital-based clinic with the 
intent to start on combination HAART. The first line treat-
ment consisted of stavudine, lamivudine, and nevirapine 
(or efavirenz for patients also on rifampicin). Selection 
criteria for the both cohorts were: aged 18 years or older, 
treatment naïve, and eligible for HAART according to 
Ugandan guidelines.33 In addition, the CBART cohort had 
to accept being visited weekly by a community volunteer 
and be willing to identify a treatment partner. Enrolment 
for both inception cohorts started on February 2006. By 
May 2006 the hospital cohort had been recruited (n = 200) 
and by April 2007 the CBART cohort had been recruited 
(n = 185); these sample sizes were based on numbers that 
we required to assess differences in treatment outcomes 
between the two cohorts for our original study objectives. 
Though the original study was not established to assess 
gender differences, we undertook a series of post-hoc sub-
analyses to look at these differences in more detail as a result 
of findings from our original study34 where we observed 
a significant difference in treatment outcomes between 
genders. With a sample size of 385, the study had adequate International Journal of Women’s Health 2010:2 47
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power of 80% with 5% level of significance to detect a 13% 
difference in the proportion of survival between males and 
females at the end of the follow-up.
Data collection
Baseline clinical and demographic data were obtained from 
the patient charts for all enrolled patients. Patient clinical 
data was collected using similar clinical forms to ensure 
comparability of the data. Demographic data included gender, 
marital status, occupation, and education. Clinical data 
included CD4+ cell counts (using a FACS Calibur machine; 
Becton Dickinson, Nairobi, Kenya). All laboratory tests were 
carried out in the laboratory of the Joint Clinical Research 
Centre (JCRC) in Fort Portal, Uganda. This center is part of 
a network of laboratories in Uganda that uses internationally 
recognized procedures for maintaining quality control and 
ensuring reliability of results. The same protocols were used 
for laboratory tests for both the CBART and hospital-based 
cohorts to ensure comparability and reliability. Mortality 
data were obtained by following up patients that had missed 
more than two visits in the hospital-based cohort and from 
community volunteers who identified deaths during their 
weekly patient visits in the CBART cohort. This study 
considered mortality from all causes.
Statistical procedures included descriptive, univariate, and 
multivariate analysis. Data from both hospital and community 
cohorts were pooled for these analyses. Significance of the 
differences in the demographic and clinical characteristics 
was tested using the chi-squared tests for categorical vari-
ables and the Mann–Whitney U test for continuous variables. 
Associations between mortality and gender were determined 
using survival analysis (Kaplan–Meier survival curves) and 
Cox proportional hazards regression. We used a purposeful 
selection of predictor variables for the final multivariate 
analysis and included either variables that were tested to 
be significant at P  0.20 in univariate analyses35 or which 
were pre-determined to be clinically important. P-values were 
two-sided and those 0.05 were considered to be statistically 
significant. We tested the proportional hazard assumption by 
plotting scaled Schoenfeld residuals for each of the covariate 
against time and by including an interaction term with time 
for each covariate.35 Martingale residuals were plotted 
against each of the continuous variables to test the linearity 
assumption.35 Age appeared to violate the linearity assump-
tion and was considered as a categorical variable in the Cox 
regression model. Overall fit of the model was assessed by 
plotting log-cumulative hazard plots of Cox–Snell residuals 
against the log-transformed Cox–Snell residuals. A straight 
line relationship with unit slope and intercept zero between 
log-cumulative hazard function of Cox–Snell residuals 
and log-transformed Cox–Snell residuals indicated that 
Cox–Snell residuals have an unit exponential distribution 
and the model-fit was satisfactory.36 Statistical analyses were 
performed using Stata software (version 10.0; Stata Corp, 
College Station, TX).37
Study approval and ethical considerations
The University of Alberta’s Health Research Ethics Board 
(Panel B) provided ethical approval for the study. In Uganda, 
approval for the study was obtained from the Uganda National 
Council of Science and Technology and by the ethical review 
committee of the School of Public Health, Makerere Univer-
sity, Kampala, Uganda. Within Kabarole District, the study 
was approved by the District Health Officer and the political 
representative of Rwimi sub-county (Local Council 3). Each 
participant was informed about the study in both written and 
verbal formats and provided written consent.
Results
A total of 385 patients were recruited into the study, of which 
222 (57.7%) were female. Overall, there were more females 
than males due to higher proportion of females seeking 
treatment Baseline data and changes in CD4+ cell counts 
for those in the study have been summarized in Table 1. 
A lower proportion of females were married compared to 
males (31.5% vs 54.0%; P  0.01) with a higher proportion 
of females being widowed, divorced or separated (48.0% 
for females vs 20.9% for males; P  0.01). In addition, 
a higher proportion of females did not have had any educa-
tion compared to males (32.4% vs 19.1%; P  0.01) and a 
smaller proportion of females had completed secondary level 
education compared to males (11.9% vs 24.1%; P  0.01). 
A higher proportion of females were unemployed (36.2% for 
females vs. 12.3% for males; P  0.01) and fewer females 
were engaged in business or employed in a professional 
capacity compared to males (25.7% vs 44.4%; P  0.01). 
Finally, females had higher baseline CD4+ cell counts than 
males (median of 147 cells/µL vs 120 cells/µL; P  0.01). 
Adherence on HAART was measured by pill counts in the 
CBART group and was found to be high for both genders; 
after six months, females had taken 98.5% of their required 
doses while males had taken 98.1% of their required doses 
(results not shown).
In our unadjusted analyses, 9.0% of all female patients died 
compared to 13.5% of male patients, but this difference was 
not statistically significant (P = 0.16). This corresponded to International Journal of Women’s Health 2010:2 48
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20.6 deaths per 100 person-years for females compared to 31.7 
per 100 person-years for males. The differences in mortality 
are displayed in Kaplan–Meier survival plots (Figure 1).
The survival curves for male and female HIV-infected 
patients show that in the first five weeks, mortality was almost 
equal in both sexes. Between five and 25 weeks, mortality was 
substantially different. In both cohorts, most deaths occurred 
in the early parts of the treatment phase. The effect size in 
the univariate analysis was a 35% difference in mortality 
in female patients compared to male patients (hazard ratio 
[HR] = 0.65; P = 0.17).
In univariate Cox regression analyses (Table 2), baseline 
CD4+ cell counts, marital status and education levels met 
the P  0.20 significance level for consideration in the 
multivariate model. Age and sex were forced into the mul-
tivariate model based on a-priori assumptions of the impor-
tance of these variables. The multivariate Cox regression 
analysis of the pooled data (Table 2) showed that females 
were less likely to die (adjusted HR = 0.55, 95% confidence 
interval [CI]: 0.28-1.07), with the differences being almost 
statistically significant (P = 0.08). Both primary education, 
compared to having no education (adjusted HR = 0.46, 95% 
CI: 0.23-0.84; P = 0.01), and a higher baseline CD4+ cell 
count (adjusted HR 0.95, 95% CI: 0.92–0.99; P = 0.02) 
were predictors of better survival. We did not observe any 
significant interactions in the multivariate model.
We also analyzed data from both cohorts separately to 
assess if gender had any relationship with mortality in the 
different delivery models for HAART. Similar to the pooled 
data, female patients had a tendency to have lower mortality 
compared to male patients, though this was not statistically 
significant (hospital cohort females adjusted HR = 0.45, 
95% CI: 0.15-1.36; P = 0.16, community-based females 
adjusted HR = 0.61, 95% CI: 0.25-1.49; P = 0.28) (results 
not shown). 
Residual analyses were carried as described in the 
methods. Only one of the covariates, education, violated the 
proportional hazard assumption and was considered as a 
stratifying variable in the final Cox regression mode but the 
overall conclusion on gender differences was not affected. 
There was almost a straight line relationship with unit slope 
and intercept zero between log-cumulative hazard function of 
Cox–Snell residuals and log-transformed Cox–Snell residuals 
indicating that the overall model fit was adequate.
Discussion
Our study provides information on the relationship between 
gender and mortality for patients on HAART in a rural area 
of Western Uganda. An important finding from this study 
is that female HIV-infected patients on HAART showed 
a tendency towards lower mortality after adjusting for 
baseline demographic variables and CD4+ cell count. 
Table 1 Demographic and clinical information of HIV patients (n = 385)
Demographic variable Male N = 163 (42.3%) Female N = 222 (57.7%) P-value
Age group, n (%)
  35 years 76 (46.6%) 117 (52.7%) 0.24*
  35+ years 87 (53.4%) 105 (47.3%)
Marital status, n (%)
  Single 41 (25.1%) 44 (20.5%) 0.29*
  Married 88 (54.0%) 69 (31.5%) 0.01*
  Widowed/Divorced/Separated 34 (20.9%) 92 (48.0%) 0.01*
Educational status, n (%)
  None 31 (19.1%) 71 (32.4%) 0.01*
  Primary 92 (56.8%) 122 (55.7%) 0.83*
  Secondary or above 39 (24.1%) 26 (11.9%) 0.01*
Occupation, n (%)
  None/Housewife 20 (12.3%) 79 (36.2%) 0.01*
  Nonprofessional/Farmer 70 (43.2%) 83 (38.1%) 0.27*
  Business person/Professional 72 (44.4%) 56 (25.7%) 0.01*
Baseline CD4 (cells/µl), median (IQR) 120 (58–183) 147 (82–206) 0.01**
All-cause mortality deaths 22 (13.5%) 20 (9.0%) 0.16*
AIDS-related deaths (in 100 person years) 31.7 20.6
Notes: *χ2 test; **Mann–Whitney test.International Journal of Women’s Health 2010:2 49
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Figure 1 Kaplan–Meier survival curve for males and females (P = 0.16 from log-rank test).
Table 2 Hazard ratios (HRs) and 95% confidence intervals (95% CIs) from Cox’s regression for factors associated with nonaccidental 
AIDS-related death
Variable Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age group
  35 years 1.00 1.00
  35+ years 0.89 (0.49, 1.64) 0.72 0.92 (0.47, 1.81) 0.82
Sex
  Male 1.00 1.00
  Female 0.65 (0.36, 1.20) 0.17 0.55 (0.28, 1.07) 0.08
Marital status
  Single 1.00 1.00
  Married 0.49 (0.23, 1.04) 0.07 0.51 (0.23, 1.12) 0.09
  Widowed/Divorced/Separated 0.56 (0.26, 1.19) 0.13 0.68 (0.30, 1.53) 0.30
Education
  None 1.00 1.00
  Primary 0.47 (0.24, 0.93) 0.03 0.42 (0.21, 0.84) 0.01
  Secondary or above 0.61 (0.24, 1.55) 0.30 0.45 (0.17, 1.21) 0.11
Occupation 1.00
  No occupation
  Nonprofessional/Farmer 0.86 (0.41, 1.81) 0.70 –
  Professional/Businessman 0.79 (0.35, 1.75) 0.56 –
  Baseline CD4+ cell count* 0.95 (0.91, 0.99) 0.01 0.95 (0.92, 0.99) 0.02
Note: *For 10 units increase in CD4+ cell count.International Journal of Women’s Health 2010:2 50
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Our analysis of gender differences within each of the 
treatment models (CBART vs hospital-based) found that 
the trend towards a lower risk of mortality for females 
remained. The effect size and the direction of the effect 
suggest that females fare better than males regardless of 
whether they were part of a rural treatment program or a 
semi-urban program and show that the association between 
gender and mortality in HAART patients may be indepen-
dent of factors that are usually associated with rural vs 
semi-urban populations (eg, cultural and socioeconomic 
differences). That outcomes are not worse in females is 
encouraging given that females tend be disadvantaged in 
terms of education and occupation and being more likely 
to be widowed, separated or divorced.
Our study findings are in line with studies in other 
sub-Saharan African countries that looked at gender 
differences in mortality for patients on HAART.8–12 In Malawi, 
one study found a significant better survival of female HIV-
infected patients on HAART compared to male patients (HR 
1.70 for males).8 A study in Cameroon found a similar higher 
risk of mortality for men (HR 1.73 for males).10 Studies in 
Nigeria, Botswana, and another in Malawi also found that 
male gender was associated with higher mortality, though 
these differences were not statistically significant.9,11,12 In 
South Africa, male gender was associated with higher early 
mortality (odds ratio [OR] 2.00), and lower later mortality 
(OR 0.58) compared to females, though the latter findings 
were not statistically significant.13 In a large multi-center 
study of mortality, researchers found that females had lower 
mortality than males in both low-income settings (HR 0.84) 
as well as high-income settings (HR 0.85), though these dif-
ferences were not statistically significant. Another study in a 
high income country, Ireland, found again that there were no 
statistically significant differences in mortality between males 
and females.38 In contrast to these findings, two studies in 
Brazil have found that females have a higher risk of mortality 
compared to men (HRs of 3.5015 and 1.8614) with these 
differences being statistically significant. With the exception 
of the Brazil studies, all other study findings corroborate our 
findings. However, it is important to note that our study is one 
of the few that evaluate gender differences in mortality for 
patients living in rural areas of sub-Saharan Africa.
One of the explanations suggested for the gender 
difference in survival is the observation that female 
HIV-infected patients enter HAART programs at an earlier 
stage of their HIV infection than men, likely through their 
participation in prevention of mother-to-child transmission 
(PMTCT) programs.8 In our cohorts, women tended to seek 
treatment earlier as apparent by the higher CD4+ cell counts 
at the time of treatment. The DART trial conducted in Uganda 
and Zimbabwe show that female HAART patients had better 
treatment outcomes, as measured by viral suppression, than 
male patients which would it make reasonable to expect that 
their survival was probably better as well.17 Unfortunately, 
the authors of the DART study did not present mortality data 
for male and female patients separately.
An important finding from our study is that female 
patients had a significantly higher CD4+ cell count at baseline 
compared to male patients and that the CD4+ cell count 
was a strong predictor of mortality. This makes it very pos-
sible that the lower mortality in our female patients is likely 
explained, at least in part, by the higher CD4+ cell count at 
the time of enrollment on HAART. This also indicates that 
females may access HAART earlier than males. This finding 
is in line with other studies from sub-Saharan Africa.8,25 
HIV-positive pregnant women have more opportunities 
for diagnosis and treatment at an earlier stage in their HIV 
infection as they access antenatal care.39 A recent study from 
Gugulethu, South Africa identifies the importance of early 
treatment and that a late start of HAART has disadvantages 
in terms if higher mortality and that this disadvantage can 
persist for years.40 Increased rates of mortality due to the late 
initiation of treatment have also been reported by Brinkhof 
and colleagues.41 The second significant association in the 
multivariate model between a lower HAART mortality and a 
better educational status is no surprise, and highlights again 
the importance of education on achieving better health, as 
shown in numerous studies. In our study, rates of mortality 
were observed to be similar between males and females 
in the first five weeks after starting treatment, with the 
differences becoming more apparent between 5–20 weeks 
after starting treatment. This suggests that the additional 
benefits of early access to treatment are realized in the later 
stages of antiretroviral treatment. In our study, six-month 
adherence was high and similar between males and females, 
thus adherence to treatment would not explain the observed 
differences in mortality.
To the best of our knowledge, the only reported biological 
differences between male and female HIV-infected patients 
on HAART are the more frequent adverse reactions to 
HAART in female HIV-infected patients. Boulassel and 
colleagues and Wester and colleagues report a higher 
incidence of lactic acidosis in female HIV-infected patients 
on HAART as compared to male HIV-infected patients on 
HAART.23,24 In addition, Boulassel and colleagues found 
that hypersensitivity reactions to ARVs were more likely International Journal of Women’s Health 2010:2 51
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to happen in female HIV-infected patients.23 The differen-
tiation between sex and gender factors impacting HAART 
outcomes and mortality is important, because biological-
based differences would be difficult to correct, but behavioral 
and social gender inequities in the health care delivery of 
HAART services could be addressed effectively by health 
care systems.
Limitations
Our sample consisted of patients who actively sought treat-
ment on their own based on a personal decision. Hospital or 
health center patients are not necessarily representative of 
all HIV-infected patients in need of treatment and may be 
different in their characteristics compared to those who do 
not attend health facilities. This may limit the generalizability 
of the study results. Finally, our study sample sizes in both 
cohorts were small, and thus the study had limited power 
to detect a statistically significant difference in mortality 
between male and female patients.
Conclusions
Our study shows that, as in the rest of sub-Saharan Africa, 
female HIV-patients in Western Uganda on HAART have 
lower mortality rates than male patients, though this is not 
conclusive. Evidence from sub-Saharan Africa suggests that 
women seek care earlier, and hence have lower mortality, 
is most likely a result of HAART programs being linked 
with maternity care for women. On the other hand, men 
seem to delay seeking treatment and enter into treatment at 
a more advanced stage of HIV infection. This may imply 
HAART programs and the associated positive outcomes 
of HAART are more readily accessible to women. If true, 
this suggests the need for more to be done to ensure that 
HIV infected men seek treatment at an earlier stage of their 
HIV infection.
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